News from targetedonc.comFollowNews from targetedonc.comSee all of targetedonc.com’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources.We’ve aggregated 510 of targetedonc.com’s headlines and news stories over the past 3 months. Ground News rates targetedonc.com’s media bias as . . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. Is targetedonc.com credible or reliable? Our Factuality score answers both of those questions. When it comes to targetedonc.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.Follow See all of targetedonc.com’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources. We’ve aggregated 510 of targetedonc.com’s headlines and news stories over the past 3 months. Ground News rates targetedonc.com’s media bias as . . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. Is targetedonc.com credible or reliable? Our Factuality score answers both of those questions. When it comes to targetedonc.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check. Information about targetedonc.comWhere is targetedonc.com located?targetedonc.com's WebsiteMedia Bias RatingsDo you diasgree? Edit biasLearn more about Media Bias Ratings.FactualityAverage Factuality Rating: UnknownLearn more about Factuality Ratings.Top targetedonc.com NewsFDA · United StatesFDA Approves First Menin Inhibitor for Acute LeukemiaCoverage: 2 sourcesThe FDA granted full approval to the menin inhibitor revumenib (Revuforj) for adults and children 1 year and older withSee the StoryFDA · United StatesAutolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) - Autolus Therapeutics (NASDAQ:AUTL)100% Center coverage: 2 sourcesAUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy) Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALL Conference call to be held on November 11 at 08:30 am EST/13:30 pm BST: conference call participants should pre-register using the link at the bottom of this press release LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeu…See the StoryBelantamab Mafodotin Triplet Boosts OS Over Daratumumab Regimen in MyelomaThe key secondary end point of overall survival was met in the DREAMM-7 trial of belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma.See the StoryLatest News StoriesTopics Most Covered by targetedonc.comCancerBreast CancerFDADNANHLCancerBreast CancerFDASources Covering Similar Topicsonclive.comcancernetwork.comPharmacy Timescuretoday.comajmc.comonclive.comcancernetwork.comPharmacy TimesSuggest a sourceLooking for a source we don't already have? Suggest one here.You've scrolled to the bottom of the feed, there are no more stories.
